US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3) of fiscal year 2025 (FY25), which ended on January 24, 2025. The company posted revenues of USD 8.3 billion, marking a 4.1% increase on an organic basis.
Segment Performance
- Cardiovascular Portfolio: Sales reached USD 3.037 billion, up 5.0% organically, driven by strong growth in Cardiac Ablation Solutions, particularly pulsed field ablation (PFA) products.
- Neuroscience Portfolio: Revenues stood at USD 2.458 billion, representing a 5.2% organic increase.
- Medical Surgical Portfolio: Generated USD 2.072 billion in sales, a 0.4% decline.
- Diabetes: Reported revenues of USD 694 million, up 10.4% organically.
Outlook
Medtronic reiterated its organic revenue growth projection for FY25, expecting growth in the range of 4.75% to 5%.-Fineline Info & Tech
